biotechnology
Merck’s $32 Billion Gambit: Decoding the High-Stakes Pursuit of a Cancer-Fighting Pioneer
Merck’s potential $32bn acquisition of Revolution Medicines signals a major shift in the oncology market. A deep dive into the finance and science behind the deal.
The Redemption Bet: Why Wall Street is Watching the World’s Most Controversial Scientist
He Jiankui, the jailed gene-editing scientist, is back. His return poses a critical question for investors: Is this a genius comeback or a catastrophic risk?
AI’s Secret Weapon Against Superbugs: Code, Cure, and the Cash Conundrum
AI can find superbug-killing drugs in days, not years. But a broken market is stopping these cures from reaching patients. Here’s the story.
The Unseen Risk: Why Modern Eugenics is the Next ESG Frontier for Finance
Modern eugenics, cloaked as genetic wellness, poses a systemic risk. For finance and investors, it’s the next frontier of ESG and ethical responsibility.
The Investor’s Paradox: What a “Thrifty Gene” Reveals About Surviving a Bull Market
A biological paradox about a ‘thrifty gene’ offers a powerful lesson for investors on rethinking risk, corporate strategy, and economic health.
The $100 Trillion Silent Pandemic: A Financial Blueprint to Avert Global Economic Collapse
Antimicrobial resistance (AMR) is a $100 trillion threat to the global economy. This article explores a financial blueprint to fix the broken antibiotic market.